This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Xeroderma Pigmentosum, Group D
Information about Xeroderma Pigmentosum, Group D: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Xeroderma Pigmentosum, Group D
Most recent studies have shown that Xeroderma Pigmentosum, Group D shares some biological mechanisms with brittle-hair, carcinoma, cockayne-syndrome, hair-diseases, hereditary-diseases, ichthyoses, lung-neoplasms, malignant-neoplasm-of-lung, malignant-neoplasm-of-skin, malignant-neoplasms, malignant-squamous-cell-neoplasm, neoplasms, non-small-cell-lung-carcinoma, skin-neoplasms, trichothiodystrophy-syndromes, xeroderma, xeroderma-pigmentosum, xeroderma-pigmentosum-complementation-group-a, xeroderma-pigmentosum-group-b, xeroderma-pigmentosum-group-g.
Among the many pathways, these few ones have gauged particular interests from scientists studying Xeroderma Pigmentosum, Group D, and have been seen in publications frequently: Cell Cycle, Cell Cycle Arrest, Cell Death, Cellular Response To Uv, Chromosome Segregation, Dna Excision, Dna Recombination, Dna Repair, Dna Replication, Hypersensitivity, Immune Response, Localization, Mitosis, Pathogenesis, Pigmentation, Programmed Cell Death, Protein Phosphorylation, Regulation Of Dna Repair, Response To Uv, Transport
Quite a number of genes have been found to play important roles in Xeroderma Pigmentosum, Group D, such as APEX1, CS, ERCC1, ERCC2, ERCC3, ERCC5, GTF2H1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, NR1H2, OGG1, TBPL1, TEAD1, TP53, TYMS, XPA, XRCC1, XRCC3. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.